LONDON, ONTARIO--(Marketwired - Oct. 15, 2013) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that pursuant to an existing consulting agreement, the Board of Directors granted 200,000 stock options (Options) to Dr. Brent Norton who is also a director of the Company, on October 15, 2013.
The Options are exercisable at a price of $0.24 and have a five year expiry term. The Options vest as follows: 50,000 immediately and 50,000 on each of December 1, 2013, March 1, 2014 and June 1, 2014.
About Critical Outcome Technologies Inc. (COTI)
COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.